Program
Pafolacianine
Also written as “CYTALUX (pafolacianine) injection”, “OTL38 for Injection” and “OTL38”.
Its studies are mostly in Ovarian Neoplasms · Lung Neoplasms, led by On Target Laboratories.
Furthest: phase 4, since Mar 9, 20263 company-led studies, 1 open or runningNext primary completion: May 28, 2027 (phase 4)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| On Target Laboratories | 31 open or running | phase 4since Mar 9, 2026 | Nov 18, 2014 | May 28, 2027phase 4 · NCT07469202 |
Also a collaborator on its studies: Medelis and SynteractHCR.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 18, 2014First study: phase 2 study in Ovarian NeoplasmsFirst studyNCT02317705 · 48 enrolled · United States
- Aug 5, 2016Phase 2 study in Lung NeoplasmsNCT02872701 · 100 enrolled · United States, Netherlands
- Mar 9, 2026Phase 4 study in Ovarian NeoplasmsNCT07469202 · 106 planned
Ahead
- May 28, 2027Primary completion: phase 4 study in Ovarian NeoplasmsNCT07469202
TargetBeta
NOC2L →read by rule
“Pafolacianine is a fluorescent imaging agent that targets folate receptors which are overexpressed in many cancers and is used with near infrared (NIR) imaging during surgery to identify tumor cells.”study text, by rule · the study
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07469202Ovarian Neoplasms | 4 | Not yet recruiting | May 28, 2027 | 106 |
| NCT02872701Lung Neoplasms · United States, Netherlands | 2 | Completed | Oct 31, 2018 | 100 |
| NCT02317705Ovarian Neoplasms · United States | 2 | Completed | Nov 2015 | 48 |
How it is read
Names in the registry
- “CYTALUX (pafolacianine) injection”, 1 entry
- “OTL38 for Injection”, 1 entry
- “OTL38”, 1 entry
Conditions, from the studies’ own filings
- Ovarian Neoplasms, 2 studies
- Lung Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.